Related Experiment Video

Updated: Mar 23, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K

[Unsolved problems of cytoprotective therapy in patients with coronary heart disease]

M E Statsenko1, S V Turkina1, A A Ermolenko1

  • 1Volgograd State Medical University, Ministry of Health of Russia, Volgograd, Russia.

Terapevticheskii Arkhiv
|March 30, 2016
PubMed

Insights

This study explores using pFOX inhibitors like trimetazidine and meldonium for heart disease. Sequential administration may enhance their effectiveness in managing myocardial ischemia.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Myocardial cytoprotection is crucial for coronary heart disease (CHD) management.
  • pFOX inhibitors, including trimetazidine and meldonium, demonstrate proven efficacy.
  • Current strategies lack a defined algorithm for differentiated use based on ischemic remodeling stages and metabolic effects.

Purpose of the Study:

  • To investigate the potential for sequential administration of meldonium and trimetazidine.
  • To explore increasing the efficacy of pFOX inhibitors in patients with CHD.
  • To address the lack of differentiated use algorithms for pFOX inhibitors.

Main Methods:

  • Review of existing data on trimetazidine and meldonium efficacy.
  • Analysis of metabolic effects of pFOX inhibitors at different ischemic remodeling stages.
  • Conceptual framework for sequential drug administration.

Main Results:

  • Trimetazidine and meldonium show proven myocardial cytoprotection in CHD.
  • No established algorithm exists for their differentiated use in various ischemic remodeling stages.
  • Sequential use of meldonium and trimetazidine is proposed as a potential strategy.

Conclusions:

  • Sequential administration of meldonium and trimetazidine may enhance pFOX inhibitor efficacy.
  • Further research is needed to define algorithms for differentiated use.
  • Optimizing pFOX inhibitor therapy could improve outcomes in acute and chronic myocardial ischemia.

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
436
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
837
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
545
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
312